相关实验视频

Updated: Jul 15, 2025

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

在B细胞急性淋巴细胞白血病中概述Para-caspaseMALT1的活性,以潜在的向治疗应用

Firas M Safa¹, Terri Rasmussen¹, Lorena Fontan²

¹Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, LA.

|September 28, 2023

概括

粘膜相关的淋巴组织淋巴瘤转位蛋白1 (MALT1) 抑制通过诱导亡,有效地杀死B细胞急性淋巴细胞白血病 (B-ALL) 细胞. 这项研究揭示了MALT1调节B-ALL中的Myc,这表明MALT1抑制剂是新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

在成年人中,B细胞急性淋巴细胞白血病 (B-ALL) 是一个重大的治疗挑战.
粘膜关联淋巴组织淋巴瘤转位蛋白1 (MALT1) 对于B细胞受体 (BCR) 介导的NF-κB信号传递至关重要,并且是其他B细胞恶性瘤的验证标.

研究的目的:

调查MALT1在B-ALL病变发生中的作用.
为了确定MALT1抑制在B-ALL中的疗效和生物效应.

主要方法:

用MALT1抑制剂 (Z-VRPR-fmk,MI-2) 治疗B-ALL细胞系.
评估细胞活力和诱导细胞亡.
对MALT1基质裂变的分析.
基因表达概况 (转录组分析) 和西部抹杀来评估MYC途径的改变.

主要成果:

通过Z-VRPR-fmk和MI-2抑制MALT1,证明了有效和选择性地杀死B-ALL细胞,包括具有费城染色体的B-ALL细胞,同时保留正常的B细胞.
细胞亡是细胞死亡的主要机制,主要影响循环细胞.
除了成熟的B-ALL.外,MALT1对其正规基质的蛋白解活性在B-ALL细胞中并未始终被检测到.
转录组分析显示,在MALT1抑制后,MYC调节基因和MYC蛋白水平的显著下调,伴随着FBXW7表达的增加.

结论:

MALT1在B-ALL中发挥着关键作用,可能独立于正规BCR信号传输.
抑制MALT1通过MYC途径失调产生抗白血病作用.
这些发现支持对MALT1抑制剂用于治疗B-ALL的临床研究.

更多相关视频

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...